Gilead Sciences GILD Ratios & Valuation
| Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | ||
|---|---|---|---|---|---|---|
| Profitability | ||||||
| Gross margin | 79.4%+1.1pp | 78.8%+0.6pp | 78.7%+2.6pp | 78.5%+2.8pp | 78.3%+2.5pp | |
| Operating margin | 34.9%+6.3pp | 34%+28.3pp | 36.1%+33.2pp | 27.9%+18.7pp | 28.6%+22.9pp | |
| Net margin | 31%+10.2pp | 28.9%+27.2pp | 27.9%+27.4pp | 21.9%+18.1pp | 20.8%+19.0pp | |
| EBITDA margin | 36.1%+6.2pp | 35.3%+28.2pp | 37.4%+33.1pp | 29.2%+16.5pp | 29.9%+18.6pp | |
| Free cash flow margin | 34.4%+0.1pp | 32.1%-3.7pp | 31.5%-1.8pp | 32.5%+7.7pp | 34.3%+5.5pp | |
| Returns | ||||||
| Return on equity | 43.2%+10.7pp | 40.5%+38.2pp | 40.5%+39.9pp | 33.3%+27.9pp | 32.5%+30.0pp | |
| Return on assets | 16.4%+5.8pp | 14.4%+13.6pp | 14.3%+14.1pp | 11.5%+9.7pp | 10.6%+9.8pp | |
| Return on invested capital | 23.7%+4.4pp | 22.2%+19.3pp | 22.7%+21.3pp | 18%+13.7pp | 19.4%+17.4pp | |
| Efficiency | ||||||
| Asset turnover | 0.5×0.0× | 0.5×0.0× | 0.5×0.0× | 0.5×0.0× | 0.5×0.0× | |
| Inventory turnover | 2.8×-0.8× | 2.8×-0.8× | 3×-1.4× | 3.6×-1.0× | 3.5×-1.0× | |
| Liquidity | ||||||
| Current ratio | 2×+0.6× | 1.6×0.0× | 1.5×+0.2× | 1.3×+0.2× | 1.4×+0.3× | |
| Quick ratio | 1.7×+0.5× | 1.3×-0.1× | 1.2×+0.1× | 1.1×+0.1× | 1.2×+0.2× | |
| Cash ratio | 0.8×+0.2× | 0.6×-0.2× | 0.6×+0.2× | 0.5×+0.2× | 0.6×+0.3× | |
| Leverage | ||||||
| Debt-to-equity | 0.9×-0.4× | 1.1×-0.3× | 1.2×-0.1× | 1.3×0.0× | 1.3×-0.1× | |
| Debt-to-assets | 0.4×0.0× | 0.4×0.0× | 0.4×0.0× | 0.4×0.0× | 0.4×0.0× | |
| Net debt / EBITDA | 1.4×-0.6× | 1.7×-6.8× | 1.6×-13.6× | 2.3×-3.5× | 2×-4.6× | |
| Interest coverage | 10.3×+2.0× | 9.8×+8.1× | 10.3×+9.5× | 8×+5.4× | 8.4×+6.7× | |
| Per Share | ||||||
| Book value per share | $18.75+23.2% | $18.09+17.4% | $17.18+16.6% | $15.68+7.3% | $15.22+8.2% | |
| Valuation | ||||||
| Market capitalization | $172.99B+23.8% | $152.28B+32.3% | $137.73B+31.9% | $133.35B+56.0% | $139.69B+53.1% | |
| Enterprise value | $187.53B+19.7% | $170.26B+28.5% | $155.34B+26.7% | $153.15B+44.4% | $156.71B+40.3% | |
| Price / earnings | 18.8×-4.6× | 17.9×-222× | 17×-811× | 21.1×-60.0× | 23.4×-165× | |
| Price / sales | 5.8×+1.0× | 5.2×+1.2× | 4.7×+1.0× | 4.6×+1.5× | 4.9×+1.5× | |
| Price / book | 7.4×+0.1× | 6.7×+0.8× | 6.4×+0.7× | 6.8×+2.1× | 7.3×+2.1× | |
| EV / EBITDA | 17.5×-0.7× | 16.4×-48.4× | 14.3×-87.9× | 18.2×-11.9× | 18.2×-17.5× | |
| EV / sales | 6.3×+0.9× | 5.8×+1.2× | 5.3×+1.0× | 5.3×+1.5× | 5.5×+1.4× | |
| Free cash flow yield | 5.9%-1.1pp | 6.2%-2.7pp | 6.7%-2.4pp | 7%-1.0pp | 7%-1.6pp | |
| Earnings yield | 5.3%+1.1pp | 5.6%+5.2pp | 5.9%+5.8pp | 4.7%+3.5pp | 4.3%+3.7pp | |
| Dividend yield | 2.3%-0.5pp | 2.6%-0.8pp | 2.9%-0.8pp | 3%-1.5pp | 2.8%-1.4pp | |
| PEG ratio | 0.3×+0.3× | 0×— | 0×— | 0×— | 0×— |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- What are Gilead Sciences's profit margins?
- Gilead Sciences (GILD) runs a 79.4% gross margin and a 34.9% operating margin, with a 31.0% net margin.
- Where do Gilead Sciences's ratios come from?
- Every ratio is computed from Gilead Sciences's SEC filings — trailing-twelve-month flows over period-end balances. Valuation multiples combine those fundamentals with market data, recomputed each period. Switch between quarterly, annual, and TTM, or open any ratio for its full history and peer comparisons.
